Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$7.66 -0.3%	$7.06	$5.47 ▼ $11.99	$159.22M	N/A	69,857 shs	16,866 shs
EGRX Eagle Pharmaceuticals	$3.19 +0.3%	$3.18	$1.50 ▼ $3.87	$41.43M	0.83	6,795 shs	341 shs
NKTX Nkarta	$2.32 +2.7%	$1.96	$1.31 ▼ $6.63	$160.51M	0.72	542,290 shs	270,473 shs
NVCT Nuvectis Pharma	$6.34 -3.1%	$7.45	$4.44 ▼ $11.80	$166.49M	-0.26	153,855 shs	33,478 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	-0.26%	-6.81%	+22.36%	-25.85%	-10.93%
EGRX Eagle Pharmaceuticals	0.00%	-0.31%	-13.55%	+59.50%	-25.99%
NKTX Nkarta	+2.65%	+5.45%	+11.54%	+32.57%	-56.88%
NVCT Nuvectis Pharma	-3.06%	-1.40%	-21.53%	-35.50%	-11.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	1.8048 of 5 stars	0.0	2.0	0.0	3.9	0.0	3.3	0.0
NKTX Nkarta	2.0324 of 5 stars	3.5	0.0	0.0	0.0	2.9	1.7	0.6
NVCT Nuvectis Pharma	3.7672 of 5 stars	3.5	3.0	0.0	0.0	3.4	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	167.62% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
NKTX Nkarta	3.00	Buy	$13.60	486.21% Upside
NVCT Nuvectis Pharma	3.00	Buy	$15.33	141.85% Upside

Current Analyst Ratings Breakdown

Latest EGRX, ACTU, NKTX, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/4/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	($0.13) per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$7.98 per share	0.40	N/A	∞
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	-19,736.59%	-281.83%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	11/6/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.17	N/A	N/A	N/A	N/A	-150.81%	-94.84%	11/4/2025 (Estimated)

Latest EGRX, ACTU, NKTX, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACTU Actuate Therapeutics	-$0.19	-$0.30	-$0.11	-$0.30	N/A	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.73	0.46
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
NKTX Nkarta	N/A	15.67	15.67
NVCT Nuvectis Pharma	N/A	2.66	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
EGRX Eagle Pharmaceuticals	85.36%
NKTX Nkarta	80.54%
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
EGRX Eagle Pharmaceuticals	28.90%
NKTX Nkarta	8.40%
NVCT Nuvectis Pharma	30.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	20.75 million	6.36 million	N/A
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
NKTX Nkarta	140	71.03 million	65.06 million	Optionable
NVCT Nuvectis Pharma	8	25.46 million	17.69 million	Not Optionable

EGRX, ACTU, NKTX, and NVCT Headlines

Recent News About These Companies

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Update

August 18, 2025 | marketbeat.com

Q3 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright

August 16, 2025 | marketbeat.com

Q3 EPS Estimates for Nuvectis Pharma Boosted by Roth Capital

August 16, 2025 | marketbeat.com

Nuvectis Pharma FY2028 EPS Forecast Raised by Roth Capital

August 15, 2025 | marketbeat.com

HC Wainwright Predicts Higher Earnings for Nuvectis Pharma

August 15, 2025 | americanbankingnews.com

Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

August 12, 2025 | finanznachrichten.de

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

August 11, 2025 | globenewswire.com

Roth Capital Forecasts Lower Earnings for Nuvectis Pharma

August 8, 2025 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS

August 6, 2025 | marketbeat.com

Nuvectis (NVCT) Q2 Loss Widens 43%

August 5, 2025 | fool.com

HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $10.00

August 5, 2025 | marketbeat.com

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

August 5, 2025 | globenewswire.com

FY2027 EPS Estimate for Nuvectis Pharma Reduced by Analyst

August 2, 2025 | marketbeat.com

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

July 31, 2025 | globenewswire.com

Nuvectis Pharma Insiders Added US$2.50m Of Stock To Their Holdings

July 29, 2025 | finance.yahoo.com

Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Nuvectis Pharma Inc News (NVCT) - Investing.com

July 18, 2025 | investing.com

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

July 8, 2025 | finance.yahoo.com

Marlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

June 25, 2025 | insidertrades.com

Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of Stock

June 21, 2025 | insidertrades.com

Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases

June 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EGRX, ACTU, NKTX, and NVCT Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$7.66 -0.02 (-0.26%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$7.66 +0.00 (+0.07%)

As of 08/21/2025 04:20 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.19 +0.01 (+0.31%)

As of 08/20/2025 12:12 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Nkarta NASDAQ:NKTX

$2.32 +0.06 (+2.65%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.28 -0.04 (-1.72%)

As of 08/21/2025 07:50 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nuvectis Pharma NASDAQ:NVCT

$6.34 -0.20 (-3.06%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$6.34 +0.00 (+0.08%)

As of 08/21/2025 07:08 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time